Area of research
Immunology · Virology
Research interest
Research focused on Cancer research and Lenvatinib, with related work in Hepatocellular carcinoma, Tumor microenvironment, CRISPR. Notable publications include 'Current applications and future perspective of CRISPR/Cas9 gene editing in cancer', 'Amplification of spatially isolated adenosine pathway by tumor–macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma', and 'PKCα/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma'.
First-principles study on strain-engineered photocatalytic performance in ferroelectric K(Ta <sub>0.5</sub> Nb <sub>0.5</sub> )O <sub>3</sub>
CLDN4 palmitoylation promotes hepatic-to-biliary lineage transition and lenvatinib resistance in hepatocellular carcinoma
Macro CD5L+ deteriorates CD8+T cells exhaustion and impairs combination of Gemcitabine-Oxaliplatin-Lenvatinib-anti-PD1 therapy in intrahepatic cholangiocarcinoma
Proteomic and metabolomic features in patients with HCC responding to lenvatinib and anti-PD1 therapy
PGAM1 Inhibition Promotes HCC Ferroptosis and Synergizes with Anti‐PD‐1 Immunotherapy
WDR4/TRIM28 is a novel molecular target linked to lenvatinib resistance that helps retain the stem characteristics in hepatocellular carcinomas
Current applications and future perspective of CRISPR/Cas9 gene editing in cancer
PKCα/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma
Amplification of spatially isolated adenosine pathway by tumor–macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma
circHMGCS1–016 reshapes immune environment by sponging miR-1236-3p to regulate CD73 and GAL-8 expression in intrahepatic cholangiocarcinoma
The progress of immune checkpoint therapy in primary liver cancer